327 filings
ARS
2023 FY
AUPH
Aurinia Pharmaceuticals Inc
3 May 24
Annual report to shareholders
4:16pm
DEFA14A
AUPH
Aurinia Pharmaceuticals Inc
3 May 24
Additional proxy soliciting materials
4:11pm
DEF 14A
AUPH
Aurinia Pharmaceuticals Inc
Definitive proxy
3 May 24
4:08pm
10-Q
2024 Q1
AUPH
Aurinia Pharmaceuticals Inc
Quarterly report
2 May 24
6:07am
8-K
AUPH
Aurinia Pharmaceuticals Inc
2 May 24
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
6:03am
8-K
b8g5t2j8t1n5 8s
29 Feb 24
Departure of Directors or Certain Officers
4:10pm
8-K
oc8wp6an9f39l1 o41
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
8-K
mpsnhbzmw2knn pr
5 Jan 24
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2023 Net Revenue Results
6:02am
8-K
fci 7mvo5d
2 Nov 23
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
6:01am
8-K
sv2wsw
21 Sep 23
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director
4:06pm
8-K
rk15flbuzs0efawxl9w
21 Aug 23
Dr. Daniel G. Billen appointed Chair of the Board of Directors
4:11pm
8-K
c038qpn7fqh8f944
3 Aug 23
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
6:03am
PX14A6G
886 8etqpez
6 Jul 23
Letter to shareholders
8:33am
8-K
31z5wy4
3 Jul 23
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
6:06am
PX14A6G
lfynway 4gy0c
1 Jun 23
Letter to shareholders
2:01pm
S-8
sf50qp8
26 May 23
Registration of securities for employees
4:39pm